Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15091848 | 1.00 | SLC6A2 (0.52) | SLC6A2KDM4EALDH1A1POLBGAA | |
| SCHEMBL6082093 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1CNR1KCNH2FFAR1 | |
| SCHEMBL1800153 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1CNR1KCNH2FFAR1 | |
| SCHEMBL1798877 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1CNR1KCNH2FFAR1 | |
| SCHEMBL1799795 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1CNR1KCNH2FFAR1 | |
| SCHEMBL2934392 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1CNR1KCNH2FFAR1 | |
| SCHEMBL23550026 | 0.82 | HTR2C (0.46) | KDM4EALDH1A1POLBGAAMAPK1 | |
| SCHEMBL19403737 | 0.82 | HTR2C (0.46) | KDM4EALDH1A1POLBGAAMAPK1 | |
| SCHEMBL23550049 | 0.82 | HTR2C (0.46) | KDM4EALDH1A1POLBGAAMAPK1 | |
| SCHEMBL19403677 | 0.82 | HTR2C (0.46) | KDM4EALDH1A1POLBGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| CN-101511797-B | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV | 2013-01-02 | — | — | CN | disclosed |
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-7951829-B2 | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| EP-2021330-B1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-22 | — | — | EP | disclosed |
| CN-101511797-A | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-19 | — | — | CN | disclosed |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | SLC6A2 1466/4885KDM4E 2796/4885ALDH1A1 528/4885 |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | BRCA1, NAT1, AADAC | SLC6A2 357/4885KDM4E 1216/4885ALDH1A1 1740/4885 |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | SLC6A2 42/4885KDM4E 3433/4885ALDH1A1 2159/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | SLC6A2 42/4885KDM4E 3433/4885ALDH1A1 2159/4885 |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | VRK1, VRK2, VIL1 | SLC6A2 1466/4885KDM4E 2796/4885ALDH1A1 528/4885 |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | SLC6A2 1466/4885KDM4E 2796/4885ALDH1A1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.